[Short-and long-term effects of cannabinoids on memory, cognition and mental illness]
- PMID: 24483000
[Short-and long-term effects of cannabinoids on memory, cognition and mental illness]
Abstract
Marijuana is considered the most commonly used drug in the world, with estimated millions of users. There is dissent in the medical world about the positive and negative effects of marijuana, and recently, a large research effort has been directed to that domain. The main influencing drug ingredient is THC, which acts on the cannabinoid system and binds to the CB1 receptor. The discovery of the receptor led to the finding of an endogenous ligand, anandamide, and another receptor-CB2. The researchers also discovered that cannabinoids have extensive biological activity, and its short and long-term effects may cause cognitive and emotional deficiencies. Findings show that the short-term effects, such as shortterm memory and verbal Learning, are reversible. However, despite the accumulation of evidence about long-term cognitive damage due to cannabis use, it is difficult to find unequivocal results, arising from the existence of many variables such as large differences between cannabis users, frequency of use, dosage and endogenous brain compensation. Apart from cognitive damage, current studies investigate how marijuana affects mental illness: a high correlation between cannabis use and schizophrenia was found and a high risk to undergo a psychotic attack. Furthermore, patients with schizophrenia who used cannabis showed a selective neuro-psychological disruption, and similar cognitive deficiencies and brain morphological changes were found among healthy cannabis users and schizophrenia patients. In contrast to the negative effects of marijuana including addiction, there are the medical uses: reducing pain, anxiety and nausea, increasing appetite and an anti-inflammatory activity. Medicalization of marijuana encourages frequent use, which may elevate depression.
Similar articles
-
Cannabis, cannabinoid receptors, and endocannabinoid system: yesterday, today, and tomorrow.Acta Pharmacol Sin. 2019 Mar;40(3):297-299. doi: 10.1038/s41401-019-0210-3. Epub 2019 Jan 22. Acta Pharmacol Sin. 2019. PMID: 30670816 Free PMC article. No abstract available.
-
Cellular and intracellular mechanisms involved in the cognitive impairment of cannabinoids.Philos Trans R Soc Lond B Biol Sci. 2012 Dec 5;367(1607):3254-63. doi: 10.1098/rstb.2011.0384. Philos Trans R Soc Lond B Biol Sci. 2012. PMID: 23108544 Free PMC article. Review.
-
An Introduction to the Endogenous Cannabinoid System.Biol Psychiatry. 2016 Apr 1;79(7):516-25. doi: 10.1016/j.biopsych.2015.07.028. Epub 2015 Oct 30. Biol Psychiatry. 2016. PMID: 26698193 Free PMC article. Review.
-
Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond.Addict Biol. 2008 Jun;13(2):147-59. doi: 10.1111/j.1369-1600.2008.00108.x. Addict Biol. 2008. PMID: 18482430 Review.
-
Beyond THC and Endocannabinoids.Annu Rev Pharmacol Toxicol. 2020 Jan 6;60:637-659. doi: 10.1146/annurev-pharmtox-010818-021441. Epub 2019 Oct 3. Annu Rev Pharmacol Toxicol. 2020. PMID: 31580774 Review.